SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018
DOI:
https://doi.org/10.33321/cdi.2020.44.46Keywords:
Vaccine safety, adverse events, immunisation, surveillance, pharmacovigilanceAbstract
Background: SAEFVIC is the Victorian surveillance system for adverse events following immunisation (AEFI). It enhances passive surveillance by also providing clinical support and education to vaccinees and immunisation providers.
This report summarises surveillance, clinical and vaccine pharmacovigilance activities of SAEFVIC in 2018.
Methods: A retrospective observational cohort study of AEFI reports received by SAEFVIC in 2018, compared with previous years since 2008. Data were categorised by vaccinee demographics of age, sex, pregnancy and Indigenous status, vaccines administered and AEFI reactions reported. Age cohorts were defined as infant (0–12 months); young child (1–4 years); school-aged (5–17 years); adult (18–64 years); and older person (65+ years). Proportional reporting ratios were calculated for signal investigation of serious adverse neurological events with all vaccines and with influenza vaccines. Clinical support services and educational activities are described.
Results: SAEFVIC received 1730 AEFI reports (26.8 per 100,000 population), with 9.3% considered serious. Nineteen percent (n = 329) attended clinical review. Annual AEFI reporting trends increased for infants, children and older persons, but were stable for school-aged and adult cohorts. Females comprised 55% of all reports and over 80% of reports among adults. There were 17 reports of AEFI in pregnant women and 12 (0.7%) in persons identifying as Indigenous Australians. A possible signal regarding serious adverse neurological events (SANE) was detected, but was not supported by signal validation testing. A clinical investigation is ongoing. Two deaths were reported coincident to immunisation with no evidence of causal association.
Conclusion: SAEFVIC continues to provide robust AEFI surveillance supporting vaccine safety monitoring in Victoria and Australia, with new signal detection and validation methodologies strengthening capabilities.
Downloads
References
Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: The model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35(4):294–8.
Clothier HJ, Crawford NW, Russell M, Kelly H, Buttery JP. Evaluation of ‘SAEFVIC’, a pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf. 2017;40(6):483–95. doi: https://doi.org/10.1007/s40264-017-0520-7.
Melbourne Vaccine Education Centre Melbourne(MVEC). [Internet.] Melbourne: SAEFVIC, MVEC; 2020. [Accessed on 3 March 2020.] Available from: https://mvec.mcri.edu.au/ .
Clothier HJ, Selvaraj G, McMinn A, Lewis G, Crawford NW, Buttery JP. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, 2012. Vic Infect Dis Bull. 2013;16(4):2–9.
World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. Uppsala monitoring centre. [Internet.] Uppsala: WHO; 2019. [Accessed on 25 July 2019.] Available from: https://www.who-umc.org/.
Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don’t aim too high: avoiding shoulder injury related to vaccine administration. Aust Fam Physician. 2016;45(5):303–6.
National Centre for Immunisation Research & Surveillance (NCIRS). AusVaxSafety. [Internet.] Sydney: NCIRS; 2016. [Accessed in January 2017.] Available from: http://www.ncirs.edu.au/vaccine-safety/ausvaxsafety/ .
Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Canberra: Australian Government Department of Health; 2018. Available from: https://immunisationhandbook.health.gov.au/.
Microsoft. Power BI. [Software.] Richmond: Microsoft Corporation; 2019. [Accessed on 27 June 2019.] Available from: https://powerbi.microsoft.com/en-us/.
Australian Bureau of Statistics. [Internet.] Canberra: Australian Government, Australian Bureau of Statistics; 2019. [Accessed on 10 September 2019.] Available from: https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Home.
Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726–30. doi: https://doi.org/10.4161/hv.34369.
Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–94. doi: https://doi.org/10.1007/s40264-014-0150-2.
Therapeutic Goods Administration (TGA). Section 19A: Guidance for industry. Supplying substitute medicines when registered medicines are unavailable or in short supply. Version 1.1, October 2017. Canberra: Australian Government Department of Health, TGA; 2018. [Accessed on 25 September 2019.] Available from: https://www.tga.gov.au/publication/section-19a-guidance-industry.
Alexander KE, Tong PL, Macartney K, Beresford R, Sheppeard V, Gupta M. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2018;36(27):3890–3. doi: https://doi.org/10.1016/j.vaccine.2018.05.078.
Crawford NW, Cheng A, Andrews N, Charles PG, Clothier HJ, Day B et al. Guillain-Barré syndrome following pandemic (H1N1) 2009 Influenza A immunisation in Victoria: a self-controlled case series. Med J Aust. 2012;197(10):574–8.
Clothier HJ, Lee KJ, Sundararajan V, Buttery JP, Crawford NW. Human papillomavirus vaccine in boys: background rates of potential adverse events. Med J Aust. 2013;198(10):554–8.
Williams SE, Pahud BA, Vellozzi C, Donofrio PD, Dekker CL, Halsey N et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine. 2011;29(46):8302–8. doi: https://doi.org/10.1016/j.vaccine.2011.08.093.
TGA. Advisory committee on vaccines meeting statement, meeting 11, 5 December 2018. [Internet.] Canberra: Australian Government Department of Health, TGA; 2018. [Accessed on 3 July 2019.] Available from: https://www.tga.gov.au/committee-meeting-info/acv-meeting-statement-meeting-11-5-december-2018.
Victorian Government. No jab, no play. [Internet.] Melbourne: Victorian Government Department of Health and Human Services; 2019. [Accessed on 25 September 2019.] Available from: https://www2.health.vic.gov.au/public-health/immunisation/vaccination-children/no-jab-no-play.
WHO. Vaccine safety net. [Internet.] Geneva: WHO; 2019. [Accessed on 3 July 2019.] Available from: https://www.who.int/vaccine_safety/initiative/communication/network/vaccine_safety_websites/en/.
Dey A, Wang H, Quinn H, Hiam R, Wood N, Beard F et al. Surveillance of adverse events following immunisation in Australia annual report, 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.29.
TGA. Database of adverse event notifications (DAEN). [Internet.] Canberra: Australian Government Department of Health, TGA; 2018. [Accessed on 20 May 2018.] Available from: https://www.tga.gov.au/database-adverse-event-notifications-daen.
Hull B, Hendry AJ, Dey A, Brotherton BJ, Macartney K, Beard F. Annual immunisation coverage report 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.47.
Kochhar S, Edwards KM, Ropero Alvarez AM, Moro PL, Ortiz JR. Introduction of new vaccines for immunization in pregnancy - programmatic, regulatory, safety and ethical considerations. Vaccine. 2019;37(25):3267–77. doi: https://doi.org/10.1016/j.vaccine.2019.04.075.
Cassidy C, MacDonald NE, Steenbeek A, Ortiz JR, Zuber PL, Top KA. A global survey of adverse event following immunization surveillance systems for pregnant women and their infants. Hum Vaccin Immunother. 2016;12(8):2010–6. doi: https://doi.org/10.1080/21645515.2016.1175697.
McHugh L, Crooks K, Creighton A, Binks M, Andrews RM. Safety, equity and monitoring: a review of the gaps in maternal vaccination strategies for Aboriginal and Torres Strait Islander women. Hum Vaccin Immunother. 2020;16(2):371–6. doi: https://doi.org/10.1080/21645515.2019.1649552.
AusVaxSafety. Pertussis vaccine safety surveillance data: pregnant women. [Internet.] Sydney: NCIRS, AusVaxSafety; 2019. [Accessed on 25 September 2019.] Available from: http://www.ausvaxsafety.org.au/safety-data/pertussis-vaccine.
Hattingh HL, Sim TF, Parsons R, Czarniak P, Vickery A, Ayadurai S. Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods study. BMJ Open. 2016;6(9):e011948. doi: https://doi.org/10.1136/bmjopen-2016-011948.
Hendry AJ, Dey A, Beard FH, Khandaker G, Hill R, Macartney KK. Adverse events following immunisation with bacille Calmette-Guérin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine. Commun Dis Intell Q Rep. 2016;40(4):E470–4.
Khandaker G, Beard FH, Dey A, Coulter C, Hendry AJ, Macartney KK. Evaluation of bacille Calmette-Guérin immunisation programs in Australia. Commun Dis Intell Q Rep. 2017;41(1):E33–48.
Gibbons CL, Mangen MJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Pub Health. 2014;14:147. doi: https://doi.org/10.1186/1471-2458-14-147.
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96.
Westphal DW, Williams SA, Leeb A, Effler PV. Continuous active surveillance of adverse events following immunisation using SMS technology. Vaccine. 2016;34(29):3350–5. doi: https://doi.org/10.1016/j.vaccine.2016.05.015.
Pillsbury AJ, Glover C, Jacoby P, Quinn HE, Fathima P, Cashman P et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8(10):e023263. doi: https://doi.org/10.1136/bmjopen-2018-023263.
Mus M, Kreijkamp-Kaspers S, McGuire T, Deckx L, van Driel M. What do health consumers want to know about childhood vaccination? An evaluation of data from an Australian medicines call centre. Aust N Z J Public Health. 2017;41(1):74–9. doi: https://doi.org/10.1111/1753-6405.12607.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
